Hikma agrees to acquire Xellia Pharmaceuticals’ assets for $135 million
LONDON: Hikma Pharmaceuticals has agreed with Copenhagen based Xellia Pharmaceuticals to acquire parts of its US finished dosage form (FDF) business and assets, including a...
Hikma and Glenmark sign agreement to commercialise Ryaltris
LONDON: Hikma Pharmaceuticals and Glenmark Specialty, a Swiss subsidiary of Glenmark Pharmaceuticals, announced the signing of an exclusive US license agreement to commercialise Ryaltris (olopatadine...
Hikma and Richter sign agreement for cariprazine
LONDON: Hikma Pharmaceuticals, the multinational pharmaceutical company, and Gedeon Richter PLC announced the signing of an exclusive license agreement to commercialise cariprazine, a novel antipsychotic,...